Evidence map›Paper›PMID 27873241›Full record

ArticleEJNMMI research2016

Predictive factors of

Alison C Johnson, Audrey Emmanuelle Dugué, Marlon Silva, Laura Moise, Xavier Tillou, Florence Joly, Nicolas Aide

Open access · goldAbstract read
In one paragraph

Article in EJNMMI research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Alison C JohnsonDepartment of Oncology, François Baclesse Cancer Center, Caen, France.
Audrey Emmanuelle DuguéDepartment of Oncology, François Baclesse Cancer Center, Caen, France.
Marlon SilvaDepartment of Radiation Therapy, François Baclesse Cancer Center, Caen, France.
Laura MoiseDepartment of Oncology, François Baclesse Cancer Center, Caen, France.
Xavier TillouDepartment of Urology, University Hospital of Caen, Caen, France.
Florence JolyDepartment of Oncology, François Baclesse Cancer Center, Caen, France.
Nicolas AideDepartment of Nuclear Medicine, University Hospital of Caen, Caen, France. aide-n@chu-caen.fr.ORCID http://orcid.org/0000-0001-9207-0847
Centre François Baclesse · FRCentre François Baclesse · LUUniversité de Caen Normandie · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe objective of this study is to explore the impact of PSA nadirs on detection rates of prostate cancer (PCa) recurrence with

methodsIn this retrospective study, data were collected from 54 patients with suspicion of PCa biochemical recurrence after EBRT (28 patients treated initially with EBRT and 26 as salvage therapy in the absence of PSA decrease after initial treatment), who underwent

resultsMedian PSA nadir was 0.31 (0.01-13.31) ng/mL, trigger PSA was 7.85 (0.47-111.60) ng/mL, and relative PSA was 6.05 (0.24-104.59) ng/mL. Overall, 40 (74%) PET/CT scans were positive: recurrence was local and/or regional in 29 patients, distant in 15 and combined both in four, with no association between PSA values and sites of recurrence. In univariate analysis, trigger (p = 0.015) and relative (p = 0.0005) PSA values and PSA velocity (p = 0.01) were significantly linked to positive PET/CT, but PSA nadir was not. In subgroup analysis, these significant differences were only found in the salvage EBRT group. Akaike Information Criterion multivariate model comparison found that relative PSA was a better predictor of positive PET/CT than trigger PSA (PSAt).

conclusionsWe found a high overall detection rate and an increase in detection rates proportional to trigger and relative PSAs. Although relative PSA, taking into account PSA nadir, was a better predictive factor of PET/CT positivity in univariate analysis, this was most noticeable for high PSAs. For low PSAs, trigger PSA remains most relevant. Larger series with intermediate PSA values need to be studied to fully apprehend nadir impact.

Indexed as

18F-choline PETBiochemical recurrenceProstate cancerPSA nadirRadiation therapy

Identifiers

PMID27873241
PMCPMC5118229
OpenAlexW2555883105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.